Navigation Links
Insulet Corporation to Report Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
Date:7/29/2008

BEDFORD, Mass., July 29 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), the leader in patch pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the second quarter 2008 on Tuesday, August 12, 2008 after the close of the financial markets.

Insulet will also host a conference call at 5:00 p.m. Eastern Time on Tuesday, August 12, 2008 to discuss its second quarter 2008 financial results. During the conference call, material information concerning the Company, its operations, strategies and prospects may be discussed.

To listen to the conference call, please dial 800-291-5365 for domestic callers and 617-614-3922 for international callers. The passcode is 10752938. A replay of the conference call will be available two hours after the start of the call through August 19, 2008 by dialing 888-286-8010 (domestic) and 617- 801-6888 (international), passcode 78058481. An online archive of the conference call will also be available by accessing the Investor Information section of the company's website at http://investors.insulet.com.

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Insulet Corporation to Present at the William Blair & Company 28th Annual Growth Stock Conference on June 19, 2008
2. Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes
3. Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
4. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
5. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
6. Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 2008
7. Insulet Corporation and DexCom Announce Development Agreement
8. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
9. Insulet Corporation to Report Third Quarter 2007 Financial Results on Wednesday, November 14th
10. Insulet Corporation Announces Pricing of Secondary Public Offering
11. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 2b 003-A1 study, known as the 003 trial, ... relapsed and refractory multiple myeloma patients. These data ... at the 51st annual meeting of the American ... in this trial is complete (n=269), and full ...
(Date:12/6/2009)... Sickle cell disease, a condition characterized ... one of the most common genetic blood disorders ... more than 70,000 Americans.(1) Research presented today at ... of Hematology highlights intriguing studies on the acute ... with this blood disorder, evaluations of both new ...
(Date:12/6/2009)... Blood clotting, or coagulation, is an important process ... is injured. Sometimes, however, clots form on the ... do not dissolve naturally, a potentially life-threatening situation ... Annual Meeting of the American Society of Hematology ... aspirin and heparin with the hope of preventing ...
(Date:12/6/2009)... 2009 A new study provides welcome news for ... thromboembolism (VTE). , The condition is estimated to ... occurs when an abnormal clot forms in a vein ... swelling. In some cases, the clot may detach from ... to the lungs, causing a potentially fatal condition known ...
(Date:12/6/2009)... Disorders information and Treatment site www.sleeping-with-a-sleeping-disorder.com ... with herbal or natural sleep aids from around ... for a good cause. The submissions will be ... Aids ,Encyclopedia, by YOU, to be sold from ... will donate 100% of the proceeds ,from sales ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2
... simple in their diet can help avert the 'cancer timebomb' facing ... ,Dr Greg Martin said that the UK is facing a 'cancer ... added that people must start eating right and exercising, as few ... of the hormone oestrogen, which can be carcinogenic. , ...
... warned against the bird flu situation in Bangladesh and ... strategy to control the deadly H5N1 strain, the FAO said. ... reported in Bangladesh, some 157,000 chickens have been culled and ... out of 64 districts since the first outbreak, announced in ...
... to data available, in 2002 almost 65,000 Americans died ... infection is the seventh leading cause of death in the ... to help ward off viral diseases, but a new report ... likelihood of catching pneumonia, at least among well-nourished women. ...
... The quote there is nothing as lovely as the feet of ... There is finally, good news from the University of Chicago Comer ... side effects of the smallpox vaccine, and unfortunately, on a toddler, ... seven weeks in the hospital and nearly died from a viral ...
... can slow their progression to dementia by having up to ... suggested . ,The study published in the May ... American Academy of Neurology. ,Mild cognitive impairment is ... used to categorize people with mild memory or cognitive problems ...
... of concentrated radio waves appears to be a safe and ... esophagus that can be a precursor of cancer . ... Barrett's esophagus, a condition associated with the continued reflux of ... lining over time. While this condition is relatively common, a ...
Other Medicine News:Health News:Simple Lifestyle Diet Changes can Diffuse 'Cancer Timebomb' 2Health News:Bird Flu: Bangladesh Situation Serious, Indian on High Alert 2Health News:Vitamins may Not Ward Off Pneumonia 2Health News:Toddler Infected With Rare Side Effect Of Smallpox Vaccination Recovering 2Health News:Toddler Infected With Rare Side Effect Of Smallpox Vaccination Recovering 3Health News:A Drink a Day may Delay Dementia Progression 2Health News:New Approach to Treating Precancerous Esophagus Condition 2Health News:New Approach to Treating Precancerous Esophagus Condition 3
(Date:12/4/2009)... today announced the three grand prize winners of Bayer,s "Express ... Brothers, selected the winning video entries submitted by children with ... in-person meeting today with Nick. ,, The winners, ... 6, from Danbury, CT, who dreams of becoming a major ...
(Date:12/4/2009)... WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: ... Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine ... antidepressants in adults with Major Depressive Disorder (MDD). SEROQUEL ... by the FDA to treat both major depressive disorder ...
(Date:12/3/2009)... ACTON, Mass., Dec. 3 Allen Medical Systems, a ... ), today announced the launch of its new Allen ... www.AllenAmatech.com . ,, The website reinforces the ... of the new product catalog, with detailed descriptions and ...
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2TeamPraxis Finishes Strong First Year of National Sales 51185 1TeamPraxis Finishes Strong First Year of National Sales 51185 2TeamPraxis Finishes Strong First Year of National Sales 51185 3TeamPraxis Finishes Strong First Year of National Sales 51185 4TeamPraxis Finishes Strong First Year of National Sales 51185 5Statement by Registered Dietitian and American Dietetic Association President Jessie M Pavlinac on Health Reform and Conservation of Natural Resource 51184 1Statement by Registered Dietitian and American Dietetic Association President Jessie M Pavlinac on Health Reform and Conservation of Natural Resource 51184 2Genoptix Inc to Announce Second Quarter 2009 Financial Results 51182 1Genoptix Inc to Announce Second Quarter 2009 Financial Results 51182 2
... N.J.--(BUSINESS WIRE)--Jun 28, 2007,- Progenics Pharmaceuticals, Inc. ... Wyeth (NYSE: WYE), today announced,positive results from ... for the treatment of opioid-induced,constipation (OIC) in ... to be presented at the Multinational Association ...
... Inc. (OTCBB: BVTI), a majority owned subsidiary of,Accentia ... interim data from the start of its fast-tracked,pivotal ... (NHL) from September 2000 through June 2006. This ... has been made available,to the Company prior to ...
Other Medicine Technology:Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5
Microwell-EIA for the detection of Insulin Autoantibody....
... color touch screen shows you the ... cassette it is ready-to-go in any ... assures accurate calibration prior to each ... with a removable, rechargeable battery, which ...
... sets the standard for testing blood ... at your patient's side - the ... self contained system can easily be ... ICU, or wherever you need it ...
... Platelet Agitators feature sturdy, ... non-slip texture coating and ... for your platelets. Helmer ... be used in Helmer ...
Medicine Products: